Brady Family Wealth LLC Purchases 222 Shares of Zoetis Inc. (NYSE:ZTS)

Brady Family Wealth LLC boosted its position in Zoetis Inc. (NYSE:ZTS) by 18.6% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 1,416 shares of the company’s stock after acquiring an additional 222 shares during the period. Brady Family Wealth LLC’s holdings in Zoetis were worth $231,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Moors & Cabot Inc. raised its stake in shares of Zoetis by 1.8% during the second quarter. Moors & Cabot Inc. now owns 14,709 shares of the company’s stock worth $2,550,000 after buying an additional 254 shares during the last quarter. Wealth Alliance grew its holdings in Zoetis by 6.2% during the 2nd quarter. Wealth Alliance now owns 12,759 shares of the company’s stock worth $2,212,000 after acquiring an additional 750 shares during the period. Meiji Yasuda Life Insurance Co raised its position in shares of Zoetis by 94.0% during the 2nd quarter. Meiji Yasuda Life Insurance Co now owns 47,922 shares of the company’s stock valued at $8,308,000 after acquiring an additional 23,225 shares during the last quarter. Mercer Global Advisors Inc. ADV lifted its stake in shares of Zoetis by 12.3% in the 2nd quarter. Mercer Global Advisors Inc. ADV now owns 49,298 shares of the company’s stock valued at $8,530,000 after purchasing an additional 5,384 shares during the period. Finally, Argent Trust Co boosted its position in shares of Zoetis by 10.2% in the 2nd quarter. Argent Trust Co now owns 22,902 shares of the company’s stock worth $3,970,000 after purchasing an additional 2,125 shares during the last quarter. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

ZTS has been the subject of a number of recent analyst reports. Stifel Nicolaus dropped their price objective on Zoetis from $210.00 to $180.00 and set a “buy” rating for the company in a report on Tuesday, January 7th. Leerink Partnrs raised Zoetis to a “strong-buy” rating in a research note on Monday, December 2nd. Leerink Partners assumed coverage on shares of Zoetis in a research note on Monday, December 2nd. They set an “outperform” rating and a $215.00 price objective on the stock. UBS Group assumed coverage on shares of Zoetis in a report on Monday, December 9th. They set a “neutral” rating and a $196.00 price objective for the company. Finally, JPMorgan Chase & Co. increased their target price on shares of Zoetis from $225.00 to $230.00 and gave the stock an “overweight” rating in a report on Friday, October 11th. One investment analyst has rated the stock with a hold rating, nine have given a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $211.89.

Zoetis Stock Up 1.7 %

Zoetis stock opened at $167.23 on Thursday. The company has a 50 day moving average of $171.31 and a 200-day moving average of $180.16. The company has a quick ratio of 2.27, a current ratio of 3.69 and a debt-to-equity ratio of 1.26. Zoetis Inc. has a twelve month low of $144.80 and a twelve month high of $200.53. The stock has a market capitalization of $75.45 billion, a PE ratio of 31.43, a price-to-earnings-growth ratio of 2.51 and a beta of 0.89.

Zoetis (NYSE:ZTS) last announced its earnings results on Monday, November 4th. The company reported $1.58 earnings per share for the quarter, topping analysts’ consensus estimates of $1.46 by $0.12. Zoetis had a net margin of 26.55% and a return on equity of 51.98%. The firm had revenue of $2.40 billion during the quarter, compared to analyst estimates of $2.29 billion. During the same period in the prior year, the business earned $1.36 EPS. The company’s revenue for the quarter was up 11.6% compared to the same quarter last year. On average, equities research analysts anticipate that Zoetis Inc. will post 5.91 EPS for the current fiscal year.

Zoetis Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, January 21st will be issued a dividend of $0.50 per share. The ex-dividend date is Tuesday, January 21st. This is an increase from Zoetis’s previous quarterly dividend of $0.43. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.20%. Zoetis’s dividend payout ratio (DPR) is presently 32.52%.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.